최신 시험

EudraCT Number: 2022-004078-53

Sponsor Protocol Number: 83403

Start Date: 2023-08-22

Sponsor Name: Academic Medical Center (AMC), department of Internal Medicine

Full Title: Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping

Medical condition: - Plaque characteristics - Systemic inflammation

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002788-30

Sponsor Protocol Number: IMVT-1401-3202

Start Date: 2023-07-13

Sponsor Name: Immunovant Sciences, GmbH

Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)

Medical condition: Thyroid Eye Disease (TED)

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	100000004853	10084358	Thyroid eye disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) BE (Ongoing) LV (Ongoing) HU (Ongoing) SK (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003584-18

Sponsor Protocol Number: KKS-307

Start Date: 2023-06-26

Sponsor Name: Philipps University Marburg

Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia

Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10021240	Idiopathic pulmonary fibrosis	PT
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10022619	Interstitial pulmonary fibrosis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000430-42

Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT

Start Date: 2023-06-22

Sponsor Name: Janssen-Cilag International NV

Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Medical condition: Major Depressive Disorder (MDD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004873	10025453	Major depressive disorder NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Ongoing) HU (Ongoing) CZ (Ongoing) PL (Ongoing) BG (Ongoing) ES (Ongoing) PT (Ongoing) SK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000692-39

Sponsor Protocol Number: IVY

Start Date: 2023-06-19

Sponsor Name: Amsterdam University Medical Center

Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva

Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10068715	Fibrodysplasia ossificans progressiva	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003594-33

Sponsor Protocol Number: EORTC-1984-BCG

Start Date: 2023-06-16

Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE)

Medical condition: Triple negative breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075566	Triple negative breast cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-001403-33

Sponsor Protocol Number: TCTLR-101

Start Date: 2023-06-06

Sponsor Name: Ascendis Pharma Oncology Division A/S

Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...

Medical condition: Locally advanced or metastatic solid tumor malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10049280	Solid tumour	LLT
	21.1	100000004864	10065143	Malignant solid tumour	LLT
	21.1	100000004864	10065147	Malignant solid tumor	LLT
	21.1	100000004864	10065252	Solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) HU (Ongoing) NL (Ongoing) PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000690-73

Sponsor Protocol Number: BAY86-5321/21912

Start Date: 2023-06-06

Sponsor Name: Bayer AG

Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...

Medical condition: Neovascular (wet) age-related macular degeneration

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10015919 - Eye disorders	10071129	Neovascular age-related macular degeneration	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000054-28

Sponsor Protocol Number: OLIGOTREAT

Start Date: 2023-06-02

Sponsor Name: Klinikum der Universität München

Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

Medical condition: Schizophrenia

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10037175 - Psychiatric disorders	10039626	Schizophrenia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002407-37

Sponsor Protocol Number: BET-PSMA-121

Start Date: 2023-05-22

Sponsor Name: Blue Earth Therapeutics Limited

Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...

Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: DE (Ongoing)

Trial results: (No results available)

최신 시험

스폰서 및 공동 작업자

건강 상태

약물 개입